http://www.unboundmedicine.com/medline/ebm/research/irinotecanUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19923868/full_citation/Cetuximab_Based_Treatment_of_Metastatic_Anal_Cancer:_Correlation_of_Response_with_KRAS_Mutational_Status_Lukan N, Ströbel P, Willer A, et al. 
Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status. [JOURNAL ARTICLE]
Oncology 2009 Nov 17; 77(5):293-299.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19923311/full_citation/Clinical_and_economic_value_of_screening_for_Kras_mutations_as_predictors_of_response_to_epidermal_growth_factor_receptor_inhibitors_Mancl EE, Kolesar JM, Vermeulen LC 
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. [JOURNAL ARTICLE]
Am J Health Syst Pharm 2009 Dec 1; 66(23):2105-2112.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920936/full_citation/Long_term_disease_free_survivor_of_metastatic_large_cell_neuroendocrine_carcinoma_of_the_lung_treated_with_amrubicin_and_irinotecan_Ryuge S, Jiang SX, Wada M, et al. 
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan. [JOURNAL ARTICLE]
Drug Des Devel Ther 2009.:213-217.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920821/full_citation/Phase_I/II_study_of_sequential_therapy_with_irinotecan_and_S_1_for_metastatic_colorectal_cancer_Yoshioka T, Kato S, Gamoh M, et al. 
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. [JOURNAL ARTICLE]
Br J Cancer 2009 Nov 17.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920819/full_citation/Metronomic_chemotherapy_with_daily_oral_etoposide_plus_bevacizumab_for_recurrent_malignant_glioma:_a_phase_II_study_Reardon DA, Desjardins A, Vredenburgh JJ, et al. 
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. [JOURNAL ARTICLE]
Br J Cancer 2009 Nov 17.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19920385/full_citation/[Chemotherapy_Induced_Myelosuppression_and_Treatment_Efficacy_in_Extensive_Stage_Small_Cell_Lung_Cancer_]Yashiki C, Hirose T, Okuda K, et al. 
[Chemotherapy-Induced Myelosuppression and Treatment Efficacy in Extensive-Stage Small Cell Lung Cancer.] [JOURNAL ARTICLE]
Gan To Kagaku Ryoho 2009 Nov; 36(11):1839-1843.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920055/full_citation/The_Effect_of_Ethanol_on_Oral_Cocaine_Pharmacokinetics_Reveals_an_Unrecognized_Class_of_Ethanol_Mediated_Drug_Interactions_Parker RB, Laizure SC 
The Effect of Ethanol on Oral Cocaine Pharmacokinetics Reveals an Unrecognized Class of Ethanol-Mediated Drug Interactions. [JOURNAL ARTICLE]
Drug Metab Dispos 2009 Nov 17.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19917990/full_citation/Bevacizumab_for_recurrent_ependymoma_Green RM, Cloughesy TF, Stupp R, et al. 
Bevacizumab for recurrent ependymoma. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Neurology 2009 Nov 17; 73(20):1677-80.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19915942/full_citation/Implications_of_KRAS_mutation_status_for_the_treatment_of_metastatic_colorectal_cancer_Ciardiello F, Tejpar S, Papamichael D 
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. [JOURNAL ARTICLE]
Target Oncol 2009 Nov 14.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19908066/full_citation/The_value_of_XPD_and_XRCC1_genotype_polymorphisms_to_predict_clinical_outcome_in_metastatic_colorectal_carcinoma_patients_with_irinotecan_based_regimens_Artac M, Bozcuk H, Pehlivan S, et al. 
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. [JOURNAL ARTICLE]
J Cancer Res Clin Oncol 2009 Nov 12.
Abstract | Full Citation